$AB

Stonehill Charles G.T. sold 5,000 shares of ALLIANCEBERNSTEIN HOLDING L.P. (AB) at $37.17 ($0.19M total) on 2026-08-04.

Strategic Execution and Platform Scaling Achieved record AUM of $905 billion, driven by a return to positive organic growth and the strongest gross sales quarter in five years. Reached the $90 billion to $100 billion private markets AUM target more than a year ahead of schedule, validating a multi-year investment strategy in corporate lending and real estate debt.

AllianceBernstein (AB) discussed Q2 2026 earnings call topics, including expectations for the Equitable Corebridge merger to add about $100B of AUM over a couple of years, with combined general account assets around $350B and separate around $200B. Management cited resilient private wealth adviser productivity, reduced expense guidance by $5-10M, and demand shifts in U.S. taxable fixed income.

AllianceBernstein Holding LP (AB) reported Q2 net income of $71.7 million, or 77 cents per share. Adjusted earnings were 82 cents per share. Revenue was $1.17 billion, with adjusted revenue of $887.5 million. The article notes AB shares down 1.5% YTD and 12% over 12 months.

AllianceBernstein (NYSE:AB) reported Q2 flows and earnings-call updates. Alternatives and multi-asset strategies drew over $4B net inflows, while active-equity outflows neared $11B and taxable fixed-income outflows exceeded $4B. Retail gross sales were $31B, yielding $900M net inflows. Private-market AUM rose to $91B. The firm raised 2026 performance-fee outlook to $115M-$135M and cut non-compensation expense guidance to $620M-$640M.

Advanced Bionics, a Sonova brand, said the US FDA approved expanded indications for its cochlear implant systems for single-sided deafness (SSD) and asymmetric hearing loss (AHL). The criteria broaden adult and pediatric eligibility, with company-cited research estimating 271,000 to 345,000 US adults with SSD and only 2.1% using CIs among eligible patients.

ALLIANCEBERNSTEIN HOLDING L.P. (AB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.01 2 a2q26earningsrelease.htm EX-99.01 2Q26 RELEASE Document Ioanis Jorgali, Investors 629.213.6139 ioanis.jorgali@alliancebernstein.com Carly Symington, Media 629.213.5568 carly.symington@alliancebernstein.com ALLIANCEBERNSTEIN HOLDING L.P. ANNOUNCES SECOND QUARTER RESULTS

AllianceBernstein (NYSE: AB) reported preliminary assets under management of $905 billion at June 30, 2026, up from $899 billion at May end. The rise was attributed mainly to firmwide net inflows, including a large low-fee passive fixed income mandate, with markets having a neutral impact. For Q2 ended June 30, net inflows were $0.7 billion.

AllianceBernstein provided a $75M loan to Rechler Equity Partners to expand Rechler Business District, a Long Island industrial business park in Medford, NY. The project includes a fully leased 140,875-sq-ft shallow-bay logistics building, 9.8 acres of leased outdoor storage, and ~45 acres for future development, per Commercial Observer/JLL.

AB Science (Euronext Paris: AB) said it completed a EUR 2.3m private placement via issuance of 3,475,758 new ordinary shares with one warrant attached each. Net proceeds will fund R&D, prioritizing AB8939 and masitinib, and extend cash coverage beyond 12 months. Shares expected to trade July 6, 2026; warrants exercisable for 60 months at EUR 0.93.